New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
07:59 EDTVCYTVeracyte weakness a buying opportunity, says Cowen
Cowen feels the recent weakness in Veracyte has created a buying opportunity despite the company's lower than expected Q2 revenues and reduced guidance. The firm calls the stock on of its top small-cap picks, citing underlying GEC growth, a strong pipeline, and low valuation. Cowen maintains its Outperform rating and $22 price target on Veracyte.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 19, 2015
16:13 EDTVCYTVeracyte performed 4,071 Afirma GEC tests in Q4
Subscribe for More Information
16:13 EDTVCYTVeracyte sees FY15 revenue $48M-$53M, consensus $59.13M
Subscribe for More Information
16:12 EDTVCYTVeracyte sees achieving 2015 Afirma GEC test volume of 19K-21K
Subscribe for More Information
16:11 EDTVCYTVeracyte reports Q4 EPS (36c), consensus (33c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use